BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//KESHO - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:KESHO
X-ORIGINAL-URL:https://kesho-kenya.org
X-WR-CALDESC:Events for KESHO
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Africa/Nairobi
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
TZNAME:EAT
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260409T190000
DTEND;TZID=Africa/Nairobi:20260509T203000
DTSTAMP:20260528T094139
CREATED:20260526T192731Z
LAST-MODIFIED:20260526T193025Z
UID:41708-1775761200-1778358600@kesho-kenya.org
SUMMARY:The Role of Multimodal Treatment in Esophageal Cancer
DESCRIPTION:Moderator: Dr. Omar Abdihamid\nSpeakers: Dr. Juma Odoro\, Dr. Rogers Mongare\, Dr. Kevin Makori\nDate: 9 April 2026\n\nThis session examined esophageal cancer management through a multidisciplinary lens\, bringing together surgical\, radiotherapeutic and systemic treatment perspectives across the continuum of care. \nA central theme was that treatment selection depends on accurate staging\, patient fitness\, disease burden and early alignment between disciplines. In many African settings\, patients may present with locally advanced disease and nutritional compromise\, making timely diagnosis\, staging and supportive care central to outcomes. \nThe surgical discussion focused on the role of resection in appropriately selected patients\, where careful assessment of resectability\, operative risk\, nodal disease and perioperative optimisation shape whether surgery can offer curative benefit. The session also reinforced that surgery is rarely a standalone decision; it must be integrated with oncology input and long-term follow-up. \nRadiotherapy was addressed as part of multimodal care\, with roles in neoadjuvant\, definitive\, adjuvant and palliative pathways depending on stage and patient factors. The discussion highlighted the need for precise planning\, symptom control and realistic treatment pathways that reflect available infrastructure and patient access. \nIn metastatic disease\, systemic therapy remains central\, with evolving use of combination approaches\, targeted treatment and biomarker-directed strategies. However\, implementation must be balanced with access\, cost\, toxicity\, performance status and local service realities. \nAcross the session\, a consistent message emerged: esophageal cancer care requires deliberate sequencing—matching the right treatment to the right patient at the right point in the disease course. \nKey Takeaways\n\nEsophageal cancer management depends on accurate staging\, nutrition assessment and multidisciplinary planning.\nSurgery remains important in resectable disease but requires careful patient selection and perioperative optimisation.\nRadiotherapy has curative\, consolidative and palliative roles within multimodal treatment.\nMetastatic disease management is evolving with systemic combinations and biomarker-driven options.\nAccess\, treatment tolerance and supportive care shape real-world implementation in Kenya and the wider region.\nEarly referral and MDT decision-making are critical to improving outcomes.
URL:https://kesho-kenya.org/event/the-role-of-multimodal-treatment-in-esophageal-cancer/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2026/05/The-Role-of-Multimodal-Treatment-in-Esophageal-Cancer-e1779823765248.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260430T190000
DTEND;TZID=Africa/Nairobi:20260430T203000
DTSTAMP:20260528T094139
CREATED:20260526T192028Z
LAST-MODIFIED:20260526T194041Z
UID:41701-1777575600-1777581000@kesho-kenya.org
SUMMARY:Multidisciplinary Management of Testicular Cancer
DESCRIPTION:Moderator: Dr. Muigai Mararo\nSpeakers: Dr. Dedan Opondo\, Dr. Joseph Abuodha\, Dr. George Ogweno\nDate: 30 April 2026\n\nThis session marked Testicular Cancer Awareness Month with a multidisciplinary discussion on diagnosis\, primary management\, advanced disease\, relapse and fertility preservation. \nA central theme was that testicular cancer is highly curable when investigated and managed promptly\, but cure depends on disciplined staging and risk stratification. Dr. Dedan Opondo outlined the importance of early clinical recognition\, scrotal ultrasound\, serum tumour markers\, cross-sectional imaging and radical inguinal orchiectomy. The session reinforced that suspected testicular cancer should not be delayed\, particularly because some germ cell tumours can progress rapidly. \nStaging was presented as a practical foundation for management. Tumour markers such as AFP\, beta-HCG and LDH\, together with nodal imaging and histology\, help distinguish seminomatous from non-seminomatous disease and guide decisions on surveillance\, chemotherapy\, radiotherapy and retroperitoneal lymph node dissection. The discussion also highlighted the technical and fertility-related implications of retroperitoneal surgery in young men. \nDr. Joseph Abuodha reviewed advanced and relapsed disease\, emphasising that treatment remains strongly anchored in surgery\, cisplatin-based chemotherapy\, radiotherapy and surveillance rather than newer targeted or immunotherapy approaches. Across stages\, the emphasis was on matching intensity to risk—avoiding both overtreatment and undertreatment—while recognising that even metastatic disease can remain curable with the right treatment strategy. \nDr. George Ogweno brought fertility preservation into the core of cancer care. He underscored the need for early oncofertility counselling\, sperm banking where possible before treatment\, and stronger collaboration between oncology\, urology\, fertility specialists\, laboratories and counsellors. The discussion also reflected Kenya’s service realities\, including limited fertility centres and the need for clearer pathways\, consent and long-term storage planning. \nAcross the session\, a consistent message emerged: testicular cancer care must protect both survival and survivorship. \nKey Takeaways\n\nEarly recognition\, tumour markers\, imaging and radical inguinal orchiectomy are central to initial management.\nRisk stratification using histology\, TNM stage and post-operative markers guides treatment intensity.\nSeminoma and non-seminoma pathways differ and should not be managed interchangeably.\nCisplatin-based chemotherapy remains central in advanced and relapsed disease.\nSurveillance is appropriate only when reliable follow-up is possible.\nFertility counselling and sperm preservation should be discussed as early as possible.
URL:https://kesho-kenya.org/event/multidisciplinary-management-of-testicular-cancer/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2026/05/Multidisciplinary-Management-of-Testicular-Cancer.png
END:VEVENT
END:VCALENDAR